Anika Therapeutics, Inc.
Anika Therapeutics develops and manufactures hyaluronic acid-based products for osteoarthritis pain management and regenerative solutions, as well as legacy products for non-orthopedic applications. Its osteoarthritis portfolio includes Orthovisc and Monovisc, viscosupplement injections for pain relief, and Cingal, a single-injection product combining hyaluronic acid with a steroid. Regenerative Solutions products include Integrity, a scaffold for tendon repair; Hyalofast, a scaffold for cartilage regeneration; and Tactoset, an injectable bone substitute. Non-orthopedic products include veterinary, anti-adhesion and ophthalmic products. Anika sells through different channels: Johnson & Johnson MedTech markets Monovisc and Orthovisc in the United States, while Anika sells regenerative products directly to U.S. clinicians and through distributors. Internationally, it sells through commercial distributors and partners. It earns money from product sales to partners and distributors, direct sales, and, in some partner arrangements, royalties on end-user sales. Anika is headquartered in Bedford, Massachusetts, where it manufactures its hyaluronic acid-based products.
No SEC Form 4 filings for $ANIK in the last 30 days.
See all $ANIK insider activity →Anika Therapeutics (ANIK) reported Q3 earnings, adjusting its 2026 revenue growth forecast to 6-10% (down from 5-10%) and raising its OEM channel growth forecast. Gross margin improved to 62%, and adjusted EBITDA rose to $5.1M. The company also announced a new distribution agreement with Boehringer Ingelheim, expecting $8M in payments. ANIK ended Q3 with $45M in cash.
Anika Therapeutics, Inc. (ANIK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Anika Reports Third Quarter 2026 Financial Results Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in Integrity TM Revenue Secured New 10-Year Hyvisc® Partnership with Enhanced Economics; Reintroduced Hyaff No
The article highlights three U.S. small-cap stocks with recent insider buying: Parke Bancorp (PBHC), Anika Therapeutics (ANIK), and Huntsman (HUN). Parke Bancorp reported Q2 2026 net income growth, while Anika Therapeutics raised earnings guidance. Huntsman's chairman made significant share purchases amid a merger with Olin Corporation. All three companies are noted for potential undervaluation.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning ANIK (Anika Therapeutics, Inc.). Coverage has skewed bullish: 5 bullish, 0 neutral, and 4 bearish.
Recent ANIK coverage spans earnings, corporate actions and financial news.
Guidance cut and modest margin outlook suggest near-term downside pressure.
Guidance raise suggests improved earnings outlook.
Guidance raise and insider buyback suggest improving outlook, but amounts are small.
Guidance raise may boost short-term upside; conservative 2027 outlook could temper longer-term expectations.
The filing is a fresh insider buy, but it is small and not a fundamental catalyst by itself.
AlphAI scores every news story that mentions ANIK with an AI model for sentiment and relevance, and aggregates insider trades from Anika Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Anika Therapeutics (ANIK) reported Q3 earnings, adjusting its 2026 revenue growth forecast to 6-10% (down from 5-10%) and raising its OEM channel growth forecast. Gross margin improved to 62%, and adjusted EBITDA rose to $5.1M. The company also announced a new distribution agreement with Boehringer Ingelheim, expecting $8M in payments. ANIK ended Q3 with $45M in cash.
Anika Therapeutics, Inc. (ANIK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Anika Reports Third Quarter 2026 Financial Results Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in Integrity TM Revenue Secured New 10-Year Hyvisc® Partnership with Enhanced Economics; Reintroduced Hyaff No
The article highlights three U.S. small-cap stocks with recent insider buying: Parke Bancorp (PBHC), Anika Therapeutics (ANIK), and Huntsman (HUN). Parke Bancorp reported Q2 2026 net income growth, while Anika Therapeutics raised earnings guidance. Huntsman's chairman made significant share purchases amid a merger with Olin Corporation. All three companies are noted for potential undervaluation.
Anika Therapeutics (ANIK) shares rose 43.4% over the past 3 months, driven by optimism around its commercial products, pipeline progress, and improving financial outlook. The company reported strong Q2 2026 results with total revenues up 16% YoY, and raised its 2026 guidance. ANIK's pipeline includes Cingal and Hyalofast, with regulatory progress ongoing. The company adopted a conservative 2027 outlook, excluding unapproved products from forecasts.
Fischetti Gary P purchased 2,000 shares of Anika Therapeutics, Inc. (ANIK) at an average of $20.53 ($20.32–$20.74) across 2 trades over 2026-08-03 to 2026-08-04.
Biotech shares hit 52-week highs on Aug. 3-4, 2026, led by catalysts including upcoming quarterly reports and clinical-trial updates. AngioDynamics (ANGO) reached $15.41, citing FDA clearance for its RELIEF study and FY2026 net sales of $320.2 million. Anika (ANIK) hit $21.11 after Q2 revenue rose to $32.6 million. Pulse (PLSE) rose to $38.29 ahead of Aug. 6 results; Eloxx (ELOX) and Yarrow (YARW) also reached highs.
Strategic Execution and Operational Drivers Achieved record commercial channel revenue growth of 17%, fueled by focused portfolio alignment and strong international demand for CINGAL and MONOVISC. Expanded gross margins to 65% by implementing a lean transformation that doubled throughput on key manufacturing lines and improved production yields.
Anika Therapeutics, Inc. (ANIK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Anika Reports Second Quarter 2026 Financial Results Commercial Channel Revenue Increased 17% to a Record $13.9 Million Delivered $3.3 Million of Net Income, 65% Gross Margin, and $7.1 Million of Adjusted EBITDA, Highest Since 2020 Raising Full-Year 2026 Financial Gui
Anika Therapeutics, Inc. (ANIK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 exh_101.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version FIFTH AMENDMENT TO CREDIT AGREEMENT This FIFTH AMENDMENT TO CREDIT AGREEMENT , dated as of July 10, 2026 (this “ Fifth Amendment ”), is entered into among ANIKA THERAPEUTICS, INC. , a Delaware corporation (the “ Bo
Anika Therapeutics, Inc. (ANIK) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 exh_101.htm EXHIBIT 10.1 Exhibit 10.1 ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN Anika Therapeutics, Inc. sets forth herein the terms of its 2017 Omnibus Incentive Plan. 1. PURPOSE The Plan is intended to enhance the ability of the Company and its Affiliates t
